CoChat
Sign Up
Cited by 94Ovarian function and disordersLipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome

Open access
Berneis, K., Rizzo, M., Hersberger, M., Rini, G. B., Di Fede, G., Pepe, I., Spinas, G. A, Carmina, E.·2009·International Journal of Clinical Practice
DOI 10.1111/j.1742-1241.2008.01897.x
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: Dyslipidaemia is very common in patients with polycystic ovary syndrome (PCOS) but, beyond plasma lipids, atherogenic lipoprotein (Lp) and apolipoprotein (apo) alterations are still ill defined. DESIGN: We measured concentrations of apoB, Lp(a) and small, dense low-density lipoprotein (LDL) in 42 patients with PCOS [age: 28 +/- 7 years, body mass index (BMI): 27 +/- 5 kg/m(2)] vs. 37 age- and BMI-matched healthy controls. METHODS: Elevated Lp(a) levels considered were those > 30 mg/dl while elevated apoB concentrations were those > 100 g/l. RESULTS: Polycystic ovary syndrome showed increased triglycerides levels (p = 0.0011) and lower high-density lipoprotein (HDL)-cholesterol concentrations (p = 0.0131) while total- and LDL cholesterol were similar. PCOS also showed smaller LDL size (p = 0.0005), higher levels of total small, dense LDL (p < 0.0001), higher concentrations of Lp(a), as considered as absolute values (p = 0.0143) and log-transformed (p = 0.0014), while no differences were found in apoB levels. Elevated Lp(a) concentrations were found in 24% of PCOS, while elevated apoB levels were relatively uncommon (14%). Spearman correlation analysis revealed that Lp(a) concentrations were weakly correlated only with HDL-cholesterol levels (r = -0.378, p = 0.0431). In addition, 36% of patients with PCOS with normal plasma lipid profile showed elevated levels of Lp(a), apoB or small, dense LDL. CONCLUSIONS: Atherogenic Lp abnormalities may be found in one-third of women with PCOS who have a normal lipid pattern. Future prospective studies are needed to test to which extent such atherogenic forms of dyslipidaemia may contribute to the increased cardiovascular risk in young women with PCOS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1742-1241.2008.01897.x

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Dyslipidemia is common in PCOS and is estimated to occur in 70% of those with PCOS.

    “Dyslipidemia is common in PCOS and is estimated to occur in 70% of those with PCOS.73, 74, 75, 76”

    From Increased Prevalence of Adverse Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome: A Canadian Population Cohort (2024) · cites this paper as [73]

    The Introduction says dyslipidaemia is very common in women with PCOS, supporting that part of the claim. Neither the Introduction nor the Results gives a 70% prevalence estimate; the Results instead reports percentages for specific lipid abnormalities. The 70% figure is therefore unsupported by this paper. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • Those with PCOS have a more adverse fasting lipid profile, positively associated with hyperandrogenemia, independent of obesity.

    “We and others have reported that those with PCOS have a more adverse fasting lipid profile, and this is positively associated with hyperandrogenemia, independent of obesity.73, 74, 75,77, 78, 79”

    From Increased Prevalence of Adverse Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome: A Canadian Population Cohort (2024) · cites this paper as [73]

    The Results report higher triglycerides and lower HDL cholesterol in women with PCOS than in BMI-matched controls, supporting a more adverse lipid profile despite similar BMI. The paper does not report a positive association between that profile and hyperandrogenemia; BMI matching also does not establish independence from all measures of obesity, as waist circumference was greater in the PCOS group. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Berneis K, Rizzo M, Fruzzetti F, Lazzaroni V, Carmina E. Athero- genic lipoprotein phenotype and LDL size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 186-9.

Cited by

Sorted by citations

Related

Authors
Berneis, K., Rizzo, M., Hersberger, M., Rini, G. B., Di Fede, G., Pepe, I., Spinas, G. A., & Carmina, E.
Affiliations
  • University Hospital Zurich (CH)
  • University of Palermo (IT)
Corresponding author
Carmina, E.
ORCID
Venue
International Journal of Clinical Practice
Publisher
Hindawi Limited
Published
2009-01
Volume
63
Issue
1
Pages
56-62
ISSN
  • 1368-5031 (ISSN-L)
  • 1742-1241
DOI
10.1111/j.1742-1241.2008.01897.x
OpenAlex
W2108215616
Cited by
94
References
49
Citations by year
2026: 5 · 2025: 2 · 2023: 6 · 2022: 9 · 2021: 4 · 2020: 7 · 2019: 2 · 2018: 4 · 2017: 5 · 2016: 5 · 2015: 8 · 2014: 3 · 2013: 4 · 2012: 7
FWCI
8.88
Type
journal article
Language
en
Open access
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 2434 d)
Locations
  • International Journal of Clinical Practice (publishedVersion)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
polycystic ovary syndrome, dyslipidemia, atherogenic lipoproteins, apolipoprotein B, lipoprotein(a), small dense LDL, HDL cholesterol, triglycerides, cardiovascular risk, women
MeSH terms
Adult, Apolipoproteins B, Cardiovascular Diseases, Female, Humans, Cholesterol, LDL, Polycystic Ovary Syndrome, Risk Factors, Body Mass Index, Case-Control Studies, Lipoprotein(a), Dyslipidemias, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review